Yoshihiro Morimoto

8PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 24, 2026
Prevalence of MSI-H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka-Colorectal Registry.

|May 04, 2026
miR-136-5p Preferentially Suppresses Cancer Stem-like Cells in Pancreatic Cancer.

|Apr 14, 2026
Therapeutic Potential of miR-4711-5p in Pancreatic Cancer: Antitumor Activity and Mechanistic Insights.

Yuhki Yokoyama, Yoshihiro Morimoto, Hiroyuki Yamamoto

|Apr 15, 2024
Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas.

Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya

|Jan 16, 2023
A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer.

Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto

|Nov 29, 2022
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.

Nami Yamashita, Yoshihiro Morimoto, Atsushi Fushimi

Pageof 2

Frequent Collaborators

3 joint publications

Atsushi Fushimi

3 joint publications

Atrayee Bhattacharya

3 joint publications

Nami Yamashita

3 joint publications

Mark D Long